Ignite Creation Date:
2024-10-25 @ 7:59 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06598839
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-09-12
Brief Title:
Immuno-effect of Tα1 for Stage I NSCLC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Assessment of the Efficacy of Immunomodulatory Therapy With Thymosin Alpha 1 Tα1 Following Surgical Resection in Patients With Stage I Non-Small Cell Lung Cancer
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the effect of thymosin alpha 1 Tα1 on postoperative peripheral blood circulating tumor cells and immunosenescence in patients with early-stage non-small cell lung cancer NSCLC
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None